Strength Seen in Parnell (PARN): Stock Moves 5.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:25AM CST
Parnell (PARN) was a big mover last session, with shares rising over 5% on the day.
PARN: 4.88 (-0.10), AKRX: 36.47 (+0.43)
Actavis' Antibiotic a Step Closer to EU Nod, CHMP Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:51PM CST
Actavis' (ACT) antibiotic, Xydalba, which is already marketed in the U.S. under the trade name Dalvance, is a step closer to EU approval.
AGN: 210.12 (+0.95), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Akorn to Present at the 33rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Fri Dec 19, 8:30AM CST
Akorn, Inc. (Nasdaq:AKRX), a specialty generic pharmaceutical company, announced today that Raj Rai, Chief Executive Officer, will provide an overview and update of the Company's business at the 33 Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 4:00 pm PST (7:00 pm EST) at the Westin St. Francis Hotel, San Francisco, California. Mr. Rai's presentation to investors will be webcast and available to interested investors and analysts.
JPM: 62.48 (unch), AKRX: 36.47 (+0.43)
AxoGen, Inc. (AXGN) Jumps 5.45% on Insider Buying - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 8:18AM CST
AxoGen, Inc. (AXGN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
AXGN: 3.85 (+0.17), AKRX: 36.47 (+0.43)
FDA clears Lannett's generic eye drug
Seeking Alpha - at Seeking Alpha - Thu Dec 18, 12:34PM CST
LCI: 42.29 (+1.79), AKRX: 36.47 (+0.43)
UCB Puts Kremers Back on Block After Scrapping $1.5B Sale
at The Street - Wed Dec 17, 8:50AM CST
Parties agree to tear up the November agreement after a regulatory hiccup.
AKRX: 36.47 (+0.43)
Dr. Reddy's Laboratories (RDY) in Focus: Stock Falls 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 8:06AM CST
Dr. Reddy's Laboratories stock fell over 7% last trading session, continuing its recent downtrend
AKRX: 36.47 (+0.43), RDY: 49.58 (-0.10)
3 Companies Growing Faster Than MannKind Corporation
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 6:03AM CST
Source: MannKind. MannKind shareholders have had quite the year. After more than doubling in the first half of the year, shares have since given back all of their gains and sit essentially unchanged. Despite the stalemate, MannKind could be on...
AKRX: 36.47 (+0.43), ALXN: 181.96 (+3.09), ACOR: 39.14 (+0.74), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Stocks Mixed In Volatile Session; Boeing Boosts Dow
at Investor's Business Daily - Tue Dec 16, 2:04PM CST
Stocks wavered and were mixed heading into the final hour Tuesday. The Dow clung to a 0.2% gain, while the S&P 500 added a fraction and the Nasdaq fell 0.4%. Volume was tracking mildly higher across the board. The Russell 2000 outperformed in the...
AKRX: 36.47 (+0.43), BA: 131.24 (+1.21), BCPC: 66.80 (-1.55), MMS: 54.94 (+0.06)
Great Stocks: Drugmaker Akorn Works On Base
at Investor's Business Daily - Mon Dec 15, 5:33PM CST
Generic-drug maker Akorn is among a few stocks in the Spotlight screen that is working on a base. Even better, the pattern is second stage, which has a better chance of success than a base that forms later in a stock's advance. The potential buy...
AKRX: 36.47 (+0.43)
Insider Trading Alert - AHC, AKRX And CNBKA Traded By Insiders
at The Street - Mon Dec 15, 9:30AM CST
Stocks with insider trader activity include AHC, AKRX and CNBKA
CNBKA: 40.34 (+0.31), AHC: 13.09 (-0.03), AKRX: 36.47 (+0.43)
Why Akorn (AKRX) is Poised to Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:03AM CST
Akorn has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
AKRX: 36.47 (+0.43)
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 27.06 (+0.21), AKRX: 36.47 (+0.43), MRK: 57.46 (+0.25), PFE: 31.42 (-0.03), ABBV: 66.21 (+1.86)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)
Energy Sector Drags On Stocks; Lakeland, Spirit, Akorn Rise
at Investor's Business Daily - Wed Dec 10, 9:28AM CST
Stocks opened in the hole Wednesday, posting quiet losses as energy stocks suffered many of the largest early declines. The Dow Jones industrial average and the S&P 500 each slipped 0.6%. The Nasdaq shed 0.4%. Volume was sharply lower, as the stock...
SAVE: 75.68 (+1.52), AKRX: 36.47 (+0.43), COST: 143.65 (-0.50), LAKE: 8.94 (+0.07), XOM: 93.78 (-0.81), VRA: 20.01 (-0.06), FRAN: 16.27 (-0.09), KKD: 19.85 (-0.04), CVX: 113.47 (-0.48), TOL: 32.74 (+0.36), HOV: 4.02 (unch)
Akorn Rises 3.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Dec 09, 5:10PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $39.01 to a high of $41.31. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $40.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 36.47 (+0.43)
Stocks Snap Back After Morning Downdraft; AutoZone Jumps
at Investor's Business Daily - Tue Dec 09, 3:16PM CST
Major averages recovered early losses Tuesday, an impressive performance considering the carnage in overseas markets overnight. At the close, the Nasdaq turned a 1.4% intraday loss into a 0.5% gain. The S&P 500 also fell more than 1% in the morning...
T: 33.96 (-0.07), BIDU: 230.98 (-2.18), SAVE: 75.68 (+1.52), AAP: 160.23 (-0.96), AZO: 617.43 (-3.87), AKRX: 36.47 (+0.43), ORLY: 193.95 (-1.11), DATA: 88.76 (+0.04), VZ: 47.67 (unch), BABA: 105.95 (+0.43)